Faculty, Staff and Student Publications

Language

English

Publication Date

9-1-2025

Journal

Nature Immunology

DOI

10.1038/s41590-025-02233-4

PMID

40707822

PMCID

PMC12414541

PubMedCentral® Posted Date

1-24-2026

PubMedCentral® Full Text Version

Author MSS

Abstract

Immunosuppressive myeloid cells are important in a variety of physiological and pathological contexts, including tumor development, but how hormones might regulate their activity is unclear. Secretogranins, a family of secretory proteins in endocrine and neuronal cells, are proposed to function as prohormones or hormones, but their specific receptors are unknown. Here we show that secretogranin 2 (SCG2), a granin family member, functionally interacts with leukocyte immunoglobulin-like receptor B4 (LILRB4) on monocytic cells. Tumor-derived SCG2 promotes tumor growth in myeloid-specific LILRB4 transgenic mice in a T cell-dependent manner, whereas SCG2 deficiency in host mice impairs tumor progression and reduces infiltration of immunosuppressive monocytic cells. Blockade of LILRB4 abrogates SCG2-induced signaling, immunosuppression and tumor growth. Mechanistically, this SCG2-LILRB4 interaction triggers SHP recruitment and SHP-independent STAT3 activation. These findings define a function for SCG2 in regulating monocytic immunosuppression and suggest that the SCG2-LILRB4 axis might be a therapeutic target.

Keywords

Animals, Receptors, Immunologic, Mice, Humans, Immune Tolerance, Mice, Transgenic, Secretogranin II, Signal Transduction, Monocytes, Mice, Knockout, Membrane Glycoproteins, Protein Binding, Mice, Inbred C57BL, Cell Line, Tumor, T-Lymphocytes

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.